A Novel Concept for the Treatment of Cancer Cachexia
About 30% of all cancer deaths are directly due to excessive loss of muscle and body
weight, called cancer cachexia. A cachectic cancer patient cannot tolerate the
required treatment leading to early death. Cachexia starts early, and today’s
clinical practice cannot deal with it.
In contrast to the prevailing view, our science strongly supports the view that to avoid
or lessen cancer cachexia, treatment of patients with PLAP must start right after tumor
detection along with the primary cancer treatment(s).
Treatment of cancer cachexia is a two-step process. First, a simple blood test,
recognized by Zoltan Laboratories to have predictive value, is used to determine which
cancer patients are most likely to develop cachexia. These patients then will receive
weekly PLAP treatments via a systemic administration route along with the prescribed
anticancer drug(s) and/or radiation.
For this and other applications (bone marrow protection, treatment of dyslipidemia)
including clinical use, recombinant plant derived PLAP with 7 days of half-life time
in the circulation will be provided by a collaborating Minnesota company.